TABLE 2.

Hypoglycemia in Hispanic and Non-Hispanic Patients During the SWITCH 2 Trial

DegludecGlargine U100Total
Patients, n (%)Episodes, nEpisodes, n /100 PYEPatients, n (%)Episodes, nEpisodes, n /100 PYEPatients, n (%)Episodes, nEpisodes, n /100 PYE
Maintenance period
Hispanic patientsn = 231n = 219n = 236
 Overall symptomatic hypoglycemia33 (14.3)117168.047 (21.5)120180.461 (25.8)237174.1
 Nocturnal symptomatic hypoglycemia18 (7.8)3651.725 (11.4)5684.232 (13.6)9267.6
 Severe hypoglycemia1 (0.4)11.42 (0.9)34.53 (1.3)42.9
Non-Hispanic patientsn = 401n = 399n = 417
 Overall symptomatic hypoglycemia109 (27.2)236195.8148 (37.1)376312.3195 (46.8)612254.0
 Nocturnal symptomatic hypoglycemia43 (10.7)6957.266 (16.5)11998.993 (22.3)18878.0
 Severe hypoglycemia9 (2.2)97.53.3 (13)1411.619 (4.6)239.6
Full treatment period
Hispanic patientsn = 241n = 241n = 258
 Overall symptomatic hypoglycemia55 (22.8)225160.064 (26.6)237172.487 (33.7)462165.9
 Nocturnal symptomatic hypoglycemia32 (13.3)7956.039 (16.2)9871.349 (19.0)17763.6
 Severe hypoglycemia2 (0.8)21.45 (2.1)75.16 (2.3)93.2
Non-Hispanic patientsn = 430n = 424n = 455
 Overall symptomatic hypoglycemia188 (43.7)630254.3213 (50.2)818332.4279 (61.3)1448293.2
 Nocturnal symptomatic hypoglycemia84 (19.5)20181.1106 (25.0)24197.9143 (31.4)44289.5
 Severe hypoglycemia13 (3.0)156.121 (5.0)2911.830 (6.6)448.9
  • Reported for the safety analysis set.